HOME >> BIOLOGY >> NEWS
Faculty of 1,000 biology launch Pharmacology & Drug Discovery Faculty

Faculty of 1000 Biology, the award-winning literature awareness service for the life sciences, today launches its much anticipated Pharmacology & Drug Discovery Faculty. The world's top pharmacologists will highlight and evaluate the most important research articles in their field. This new faculty is headed by world-renowned pharmacologists Floyd Bloom & Paul Insel and comprises 14 sections; each led by top scientists in those fields.

"Making use of the essential advances outside your own specialist subject area can mean the difference between success and failure. Faculty of 1000 Biology now offers a timely guide by key opinion leaders to the important developments in any area of Pharmacology & Drug Discovery, joining, by popular demand, coverage of the rest of Biology," says Dave Weedon, Managing Director of Faculty of 1000 Biology.

Faculty head Floyd Bloom is a past Editor-in-Chief of Science and Professor Emeritus at The Scripps Research Institute in La Jolla. He welcomes the development of the Pharmacology & Drug Discovery Faculty, "No one can keep up with the literature, so having colleagues point out the recent important advances in unfamiliar areas is enormously useful."

Faculty head Paul Insel is Professor of Pharmacology and Medicine and Director of the Medical Scientist Training Program, University of California, San Diego. For him, the value of this new service is clear, "In the current era, science moves too fast and the literature is too vast for any of us to be 'ahead of the curve'. Faculty of 1000 helps busy, engaged scientists to navigate the rapidly changing scientific road. This is particularly the case in the broad worlds of Pharmacology and Drug Discovery."

These respected leaders in the field have helped recruit over 200 experts to act as Section Heads and Faculty Members. A full list of the researchers involved in this new faculty is available on the Faculty of 1000 Biology website <

Contact: Grace Baynes
press@facultyof1000.com
44-207-631-9988
BioMed Central
30-Oct-2006


Page: 1 2

Related biology news :

1. Agns Vignery, osteoporosis researcher, named Yale-Pfizer Visiting Faculty
2. Faculty of 1000 Biology launch ecology faculty
3. Joslin Diabetes Center awards 1st Mary K. Iacocca Faculty Fellowship
4. 1,000-year-old Arctic ponds disappearing due to global warming
5. Scientists win grants to develop $1,000 genome sequencing technology
6. Students discover 11,000 year old remains of Irish Elk
7. Expression Project for Oncology (expO) collects 1,000th malignant tumor specimen
8. A step toward the $1,000 personal genome using readily available lab equipment
9. New textbook illuminates the close links between evolutionary and molecular biology
10. University of Leeds strengthens China links in membrane and neurobiology
11. Probing biologys dark matter

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Faculty biology launch Pharmacology Drug Discovery Faculty

(Date:5/20/2013)... resistant to the antibiotic colistin are also commonly ... body, according to a study in mBio ... Society for Microbiology. Cross-resistance to colistin and host ... body against bacterial attack, could mean that patients ... with a crippled immune response. Colistin is a ...
(Date:5/20/2013)... Science Foundation (NSF) planning grant will help establish the ... program of the University of Illinois at Urbana-Champaign and ... will be devoted to research in drying moist, porous ... and paper products; chemical products; textiles; and biopharmaceuticals," said ... science and human nutrition and the Illinois site director. ...
(Date:5/19/2013)... strain of electricity-producing bacteria that can grow using hydrogen ... as its sole source of carbon. Researchers at ... the 113th General Meeting of the American Society for ... production solely on hydrogen," says Amit Kumar, a researcher ... part of the Lovley Lab Group at the university. ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... , May 21, 2013 According ... Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market ... - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," ... 2011 and is expected to grow at a CAGR ... estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... 21, 2013 Many have long discussed ... to acne. Recently physicians from Clinical Psychiatry.com ... on the skin, and suggested using hypnotherapy ... chemicals produced from stress that cause acne. , Doctors ... feelings acne brings about, stress causes changes in the ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: